试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 552
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
Imatinib PD in healthy subjectsImmuno-oncology assessmentsCTIS2023-504958-35-00Centre for Human Drug Research36
进行中（未招募）
1 期
A SINGLE-CENTER, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO ASSESS SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF REPEAT DOSES OF ARM210 IN HEALTHY SUBJECTS.Cardiac arrhythmiasMedDRA version: 20.0Level: HLGTClassification code: 10007521Term: Cardiac arrhythmias Class: 10007541CTIS2023-509086-20-00Armgo Pharma Inc.8
进行中（未招募）
1 期
TROPHAMET, a phase I/II trial of Avelumab and METhotrexate in low-risk gestational TROPHoblastic neoplasias as first line treatmentow-risk gestational trophoblastic neoplasiaMedDRA version: 20.0Level: LLTClassification code: 10018211Term: Gestational trophoblastic tumor NOS Class: 10029104CTIS2024-515434-32-00Hospices Civils De Lyon26
进行中（未招募）
1 期
Study of RP2 alone and in combination with PD1 Blockade in patients with solid tumoursSolid tumorsMedDRA version: 21.0Level: LLTClassification code: 10049280Term: Solid tumour Class: 10029104CTIS2024-512866-32-00Replimune Group Inc.86
进行中（未招募）
1 期
Multicentric Phase 1 Study With Escalation of Doses of Daratumumab in Combination With Chemotherapy (Idarubicin and Cytarabine) or CPX-351 in Patients of 60 years old or more With adverse Risk Acute Myeloblastic Leukemia (AML) (DARALAM)Adult patients with adverse Risk Acute Myeloblastic LeukemiaCTIS2022-502585-25-00Centre Hospitalier Universitaire De Nantes12